Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EB-1020 dose-ranging placebo-controlled trial in children and adolescents with ADHD
jRCT2071250045Phase 3Recruiting
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of centanafadine in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Change from baseline in ADHD-RS-5 symptom total raw score at Week 6. Started Sep 2025; status: recruiting.
02
Drugs
centanafadine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on jRCT2071250045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250045.